Connect with us

International

Amid massive turnover, Agios hires Biogen alum as new CFO; Scholar Rock, Everest Medicines lead the big CEO parade

Cecilia Jones
When Cecilia Jones started at Genzyme, there was next to nothing in Kendall Square.
“It was just us,” Jones said. “There wasn’t much…

Published

on

Cecilia Jones

When Cecilia Jones started at Genzyme, there was next to nothing in Kendall Square.

“It was just us,” Jones said. “There wasn’t much to even go for lunch.”

Jones would work in Cambridge, MA, for the next 17 years — spending seven at Genzyme and 10 at Biogen, where she would go on to hold a VP role in finance — as Kendall Square and Cambridge grew into a biotech hub.

“It’s like night and day,” Jones said of the area now.

On Monday, Jones will return to Cambridge as the CFO of Agios, following a two-year stint at LogicBio (located less than 10 miles outside Cambridge).

Jones joins Agios as the biotech is going through a period of continuous churn. In late 2020, Agios announced it was selling off its entire cancer portfolio, including Tibsovo, an AML drug. Since then, it has pivoted to rare diseases, starting with Pyrukynd, a drug for pyruvate kinase deficiency, which got its first approval in February of this year.

In May, amid a larger market downturn, Agios laid off some 50 employees, and then in July, its CSO Bruce Car departed. Soon after, Jackie Fouse handed the CEO seat to Brian Goff, as Fouse transitioned to board chair.

When asked about the turnover at Agios, Jones said, “I asked them the same questions.”

But for Jones, Agios’ new look as a rare disease biotech was an attracting factor. She first worked in rare diseases at Genzyme, where she said she developed her passion for the field. “To me, being part of an organization that has the potential to make this positive impact on people with rare and genetically-defined diseases is incredibly rewarding. Obviously I don’t discover drugs, I don’t work in the lab, but I support the groups that do that,” Jones said.

On Goff coming on as CEO, Jones said, “That was actually one of the things that attracted me to the job too, is Brian has a lot of rare disease expertise and commercial experience with launching rare disease drugs, so I think he was a perfect fit to try to lead the company in the next phases.”

Jones moved to the US in 2000 to get her MBA from Harvard Business School. After graduating, she decided to stay in the US and landed her first job at Genzyme. “I had no background in biotech and had never worked in pharma or anything like that,” Jones said. “It was a completely new challenge for me. And this was also 20 years ago — I feel like biotech has become much more popular and much more known.”

“In Argentina,” Jones said, where she grew up, “definitely, biotech was very nascent, and nobody knew much about it.”

But Jones has stayed with the Boston-area biotechs.

“I question that every winter,” Jones joked. She then added, “I’ve stayed very loyal to Massachusetts. I still have my Argentina roots, and I do go back home every year, but it’s been 22 years now.”

Lei Lei Wu


Jay Backstrom

Scholar Rock founder Nagesh Mahanthappa took it upon himself to fill in as CEO when Tony Kingsley ultimately left for Versant protein stabilization biotech Stablix. But he’ll soon roll out the welcome mat for new chief executive Jay Backstrom, the R&D chief at Acceleron before Merck’s $11.5 billion M&A play last year. The ex-Celgene CMO and head of global regulatory affairs also adds to his collection of board appointments, which includes Autolus Therapeutics, Be Biopharma, Disc Medicine and Lava Therapeutics. When Backstrom gets settled on Oct. 20, Mahanthappa will relinquish his seat on the board of directors and become a strategic advisor.

Rogers Yongqing Luo

Everest Medicines has quickly filled the CEO slot that Kerry Blanchard left vacant in late August. Rogers Yongqing Luo had spent the last two years as president and general manager for Greater China at Brii Biosciences, and he helped get eight drugs past the finish line as Everest partner Gilead’s global VP and China general manager. In June, Everest celebrated its Trodelvy approval in China, and Gilead then shelled out $280 million upfront for rights to the drug in China and select countries in Asia. Ten days after the deal was made, Blanchard called it quits.

Mark Rothera

Mark Rothera has resurfaced as president and CEO of San Diego cancer biotech Viracta Therapeutics. In February, Rothera stepped aside as chief executive of UK RNAi player Silence Therapeutics and left his CFO, Craig Tooman, in charge with little explanation, but our Max Gelman indicated that Tooman’s M&A credentials could’ve been a factor in his appointment. Silence has cycled through a number of CEOs in the last five years, from Ali Mortazavi to David Horn Solomon (now with Pharnext) to Rothera’s appointment in September 2020 after his stint as CEO of Orchard Therapeutics. Viracta’s lead program, a combination of nanatinostat and valganciclovir (nana-val), is in a Phase II trial for relapsed/refractory Epstein-Barr virus-positive lymphoma.

Abigail Jenkins

→ A new era has dawned at Gamida Cell, where Julian Adams is retiring and Abigail Jenkins has replaced him as president and CEO. Formerly the chief commercial and business officer at Lyndra Therapeutics, Jenkins was business unit head of vaccines at Emergent BioSolutions, exiting the Baltimore company just as things really started to go sideways with the production of J&J’s Covid-19 jab. Gamida Cell’s decision day with the FDA on its cell therapy omidubicel is Jan. 30, 2023. Amber Tong has more on Adams’ retirement.

Matthias Alder

Gain Therapeutics has promoted Matthias Alder to CEO, as Eric Richman concentrates on his duties as a board member and senior advisor. As we pointed out at the time, Alder came to the protein misfolding biotech almost a year ago as COO, moving on from his CBO post at Autolus. From 2014-17, he was EVP, business development & licensing, general counsel and corporate secretary for Sucampo Pharmaceuticals. Richman is a 12-year MedImmune vet who took over as Gain’s CEO in July 2020 and guided the Bethesda, MD biotech to its modest IPO in March 2021, but its stock $GANX has taken a beating ever since, an unsurprising turn of events in the current bear market.

Jodie Morrison

→ There’s a changing of the guard at Q32 Bio, now teaming up with Horizon on the anti-IL-7Rα antibody ADX-914: Atlas Venture partner Jodie Morrison has been named acting CEO as former Goldfinch Bio exec Michael Broxson walks out the door. Morrison — the former chief executive at Cadent Therapeutics until it was sold to Novartis — takes a seat on the board and she’ll also preside over Q32 Bio’s program for complement disorders, ADX-097, which is in an early-stage trial.

→ One week removed from ex-Trillium chief Jan Skvarka’s appointment to the board of directors, Zentalis has poached Carrie Brownstein from Cellectis, naming her CMO. While she was medical chief at Cellectis, Brownstein started her tenure inauspiciously when a patient death prompted a clinical hold of the French biotech’s off-the-shelf CAR-T drug for multiple myeloma, a study that would resume four months later. Brownstein, a former senior medical director at Roche and a Regeneron oncology vet, was VP of global clinical R&D during her three years at Celgene.

Piyush Sharma

Alnylam has made a pair of appointments as it claims a win with patisiran in ATTR amyloidosis with cardiomyopathy. Piyush Sharma (chief ethics & compliance officer) is a Pfizer alum who was head of compliance at Alexion once it became part of the AstraZeneca universe. And Evan Lippman (Alnylam’s first chief corporate development and strategy officer) says goodbye to Alessandro Riva’s crew at Intima Bioscience, where he was president and COO. During a four-year run with Takeda, Lippman served as SVP, head of corporate development, M&A and valuation.

Eliseo Salinas

Eliseo Salinas’ next landing spot is with Delix Therapeutics, the Boston neuro biotech that launched in 2019 and nabbed $70 million in Series A financing almost exactly a year ago. Salinas, who signed on as R&D chief at Delix, had the same title at Passage Bio and split the scene in the midst of a reorg in March that refocused the pipeline and shaved off 13% of the staff. (CEO Bruce Goldsmith would later step down.) In May 2021, Salinas took over as interim medical chief when Gary Romano resigned mere days after CFO Richard Morris also decided to pack his bags. Prior to his time at Passage Bio, Salinas was CSO at Shire and Acadia Pharmaceuticals.

Lisa French

→ Pulled to the surface from the quicksand of bankruptcy and opioid litigation, Mallinckrodt has recruited Lisa French as chief commercial officer after last week’s FDA approval of terlipressin. French replaces Hugh O’Neill and comes from Merck spinoff Organon, where she was the US women’s health business unit lead. She had a nearly 30-year career with the pharma giant that concluded as associate VP, US marketing lead for the HPV franchise before her move to Organon. Branded as Terlivaz, terlipressin earned the OK for adults with hepatorenal syndrome, but it does come with a black box warning.

Shulamit Ron-Bigger

Aktis Oncology is on easy street — first house down — following an $84 million raise in late August, and as the radiopharmaceuticals space continues to heat up, Matthew Roden’s squad has installed Shulamit Ron-Bigger as COO. Leaving Big Pharma behind, Ron-Bigger had led strategy and operations for Bristol Myers Squibb’s research and early development organization.

Glenn Pauly

→ As Alzheon touts its Alzheimer’s drug ALZ-801 without any clinical data to show for it — and the Framingham, MA biotech has a penchant for patting itself on the back a bit too hard with the data it does gather — it’s enlisted Glenn Pauly as head of commercial. Pauly has familiarity with the space from his days at Biogen, where he was US western division general manager and VP in charge of commercialization for the ill-fated Alzheimer’s drug Aduhelm. After holding sales roles at Genentech from 2008-17, Pauly became AstraZeneca’s senior director, market access, respiratory biologics.

Gemma Brown

→ AstraZeneca’s Covid-19 partner Vaccitech has elevated Gemma Brown to CFO after a year as the Oxford spinout’s head of financial reporting. Brown had previously held a number of roles, including senior manager at EY from 2012-21. Despite AstraZeneca’s clash with the EU on supply issues, and concerns over blood clots with the Covid-19 vaccine it co-invented, Vaccitech’s IPO exceeded nine figures in April 2021, but its stock $VACC is down more than 75% since its Nasdaq debut. Regarding the development of Vaxzevria, AstraZeneca CEO Pascal Soriot told the BBC in June, “I don’t think I would do anything differently from what we did.”

Phillip Samayoa

→ Coming off a major letdown with its hemophilia A gene therapy in which shares were routed, Generation Bio has promoted Phillip Samayoa to chief strategy officer. When he was a principal at Atlas Venture from 2016-18, Samayoa co-founded Generation Bio and Dyne Therapeutics, joining Generation Bio’s team as senior director (and then VP) of strategy and portfolio development. After co-founding Codiak BioSciences during his time at Flagship Pioneering, Samayoa jumped over to Merck as director of MRL Ventures Fund.

→ To start this month, Ashleigh Palmer’s Provention Bio took out a $125 million loan with Hercules Capital before the FDA reaches a verdict on the BLA resubmission for anti-CD3 type 1 diabetes drug teplizumab. This week the New Jersey biotech has lined up NIBR human resources vet Sarah O’Brien as chief people officer. The former head of HR in North America for Sobi, O’Brien had been chief people officer before with Relay Therapeutics and, since last year, Ardelyx. Provention is trying to get off the mat with teplizumab after receiving a CRL for the ex-Eli Lilly drug in July 2021.

Cindy Cao

Cindy Cao has replaced Bill Tente as chief regulatory officer of Humacyte, although Tente will stick around at the Laura Niklason-led regenerative medicine shop as an executive advisor. She had led regulatory affairs and quality assurance at Ascentage Pharma since 2018, but Cao has plenty of Big Pharma experience from Sanofi, Novo Nordisk and Bristol Myers. One more quick note: Former Air Force Surgeon General Bruce Green has joined Humacyte’s board of directors.

→ Returning from a nearly two-year break that he described on his LinkedIn as, “Retired. Golfed. Shaved a few strokes off my handicap,” ex-Shire HR chief Peter Lasky is making all the clutch putts as chief people officer of Waltham, MA antibody biotech DynamiCure. Before he worked on his game, Lasky was SVP, human resources at Deciphera and the chief HR officer at Wave Life Sciences.

Oliver Ernst

Neuway Pharma, which is working on new ways of delivering drugs to the brain, is ushering in some new changes to its exec team with the promotion of Oliver Ernst to CEO and the appointment of Thomas Christoph as chief development officer. Ernst joined Neuway in 2019 as COO and managing director — having formerly served in roles at Brainlab and BASF. Ernst takes over the reins from co-founder, Heiko Manninga, who will continue to serve as CSO and managing director. Meanwhile, Christoph joins the German company from Gruenenthal, where he led pharmacology and preclinical development teams.

Ruth Thieroff-Ekerdt

→ Aging-focused Cambrian BioPharma has pulled in Ruth Thieroff-Ekerdt as EVP of clinical development. Thieroff-Ekerdt formerly served as scientific advisor at Organon and acting CMO at Forendo. Her career also spans stints as CMO at Sojournix, Aptalis, Strongbridge and Kaleido and R&D roles at Bayer.

→ Université Libre de Bruxelles spinoff NeuVasQ Biotechnologies has locked in Emmanuel Lacroix as CEO and company director. Lacroix hails from UCB Ventures, where he was founding VP and partner. Earlier in his career, Lacroix was with UCB and Cellectis.

Beth Burnside

→ Austin, TX-based Maxwell Biosciences has brought aboard three new execs with the appointments of Tony Verco (CMO), Beth Burnside (SVP of R&D strategy), and Donald Treacy (SVP, development operations). Verco joins up with the team at Maxwell with experience under his belt from roles at Shelton Clinical Research Consultants, Medwell Capital, Endpoint Research and AstraZeneca. Meanwhile, Burnside has had gigs at Lowery Creek Consulting, QRxPharma, MiddleBrook Pharmaceuticals and Shire; while Treacy has served at Magothy Consulting Group (CEO), MiddleBrook Pharmaceuticals (SVP of development and manufacturing operations), and Shire (senior director of analytical sciences).

Scott Chaplin

Berkeley Lights is bringing in some firepower with the appointment of Scott Chaplin as chief legal officer and corporate secretary. Chaplin joins from Shield AI, where he was chief legal and people officer. Prior to Shield, Chaplin was with Vista Outdoor, Alliant Techsystems and Stanley.

→ CDMO ViroCell has brought on Susan Nichols as CBO. Nichols currently has a seat on the board of the Alliance for Regenerative Medicine. Nichols brings with her experience from her time as an executive officer at Propel BioSciences and CEO of Falcon Therapeutics.

Sek Kathiresan

Jason Coloma’s Maze Therapeutics has reserved space for Verve Therapeutics CEO Sek Kathiresan on the board of directors. Verve’s Phase Ib trial is ongoing with its cardiovascular drug — a single base editor named VERVE-101 — and Kathiresan’s crew has teamed up with Vertex in a gene editing deal worth $60 million upfront.

Charles Baltic is succeeding Christine White as chair of MEI Pharma’s board. A board member at the San Diego cancer biotech since 2011, Baltic had been a senior advisor with Needham & Company, where he was also managing director and co-head of healthcare banking.

Eric Ende

Eric Ende will take over for Herbert Conrad as chairman of Matinas BioPharma on Oct. 1, although Conrad will stay on the board. Ende, an ex-Merrill Lynch biotech analyst, also sits on the boards of Avadel Pharmaceuticals and NeuBase Therapeutics.

→ One of the few biotechs willing to brave the Nasdaq elements with an IPO this year, PepGen has welcomed Habib Dable to the board of directors. This is the third time in as many months that the former Acceleron CEO has popped up in this part of Peer Review after board appointments at Blueprint Medicines and Albireo.

Lauren Silvernail

Under the leadership of CEO Julie Eastland, Harpoon Therapeutics has elected ex-Revance CFO and CBO Lauren Silvernail to the board of directors. The Allergan vet just spent four years as CFO and EVP of corporate development at Evolus.

Winston Kung is headed to the board of directors at Merck’s T cell engager partner Janux Therapeutics. Kung is a Celgene vet who handles the roles of COO and CFO at p53 biotech PMV Pharma.

→ CNS-focused Pasithea Therapeutics has brought in ex-Biosense CEO Alfred Novak to the board of directors after Yassine Bendiabdallah’s exit. Last week, Pasithea named Merit Cudkowicz to its scientific advisory board.

Read More

Continue Reading

Government

Four Years Ago This Week, Freedom Was Torched

Four Years Ago This Week, Freedom Was Torched

Authored by Jeffrey Tucker via The Brownstone Institute,

"Beware the Ides of March,” Shakespeare…

Published

on

Four Years Ago This Week, Freedom Was Torched

Authored by Jeffrey Tucker via The Brownstone Institute,

"Beware the Ides of March,” Shakespeare quotes the soothsayer’s warning Julius Caesar about what turned out to be an impending assassination on March 15. The death of American liberty happened around the same time four years ago, when the orders went out from all levels of government to close all indoor and outdoor venues where people gather. 

It was not quite a law and it was never voted on by anyone. Seemingly out of nowhere, people who the public had largely ignored, the public health bureaucrats, all united to tell the executives in charge – mayors, governors, and the president – that the only way to deal with a respiratory virus was to scrap freedom and the Bill of Rights. 

And they did, not only in the US but all over the world. 

The forced closures in the US began on March 6 when the mayor of Austin, Texas, announced the shutdown of the technology and arts festival South by Southwest. Hundreds of thousands of contracts, of attendees and vendors, were instantly scrapped. The mayor said he was acting on the advice of his health experts and they in turn pointed to the CDC, which in turn pointed to the World Health Organization, which in turn pointed to member states and so on. 

There was no record of Covid in Austin, Texas, that day but they were sure they were doing their part to stop the spread. It was the first deployment of the “Zero Covid” strategy that became, for a time, official US policy, just as in China. 

It was never clear precisely who to blame or who would take responsibility, legal or otherwise. 

This Friday evening press conference in Austin was just the beginning. By the next Thursday evening, the lockdown mania reached a full crescendo. Donald Trump went on nationwide television to announce that everything was under control but that he was stopping all travel in and out of US borders, from Europe, the UK, Australia, and New Zealand. American citizens would need to return by Monday or be stuck. 

Americans abroad panicked while spending on tickets home and crowded into international airports with waits up to 8 hours standing shoulder to shoulder. It was the first clear sign: there would be no consistency in the deployment of these edicts. 

There is no historical record of any American president ever issuing global travel restrictions like this without a declaration of war. Until then, and since the age of travel began, every American had taken it for granted that he could buy a ticket and board a plane. That was no longer possible. Very quickly it became even difficult to travel state to state, as most states eventually implemented a two-week quarantine rule. 

The next day, Friday March 13, Broadway closed and New York City began to empty out as any residents who could went to summer homes or out of state. 

On that day, the Trump administration declared the national emergency by invoking the Stafford Act which triggers new powers and resources to the Federal Emergency Management Administration. 

In addition, the Department of Health and Human Services issued a classified document, only to be released to the public months later. The document initiated the lockdowns. It still does not exist on any government website.

The White House Coronavirus Response Task Force, led by the Vice President, will coordinate a whole-of-government approach, including governors, state and local officials, and members of Congress, to develop the best options for the safety, well-being, and health of the American people. HHS is the LFA [Lead Federal Agency] for coordinating the federal response to COVID-19.

Closures were guaranteed:

Recommend significantly limiting public gatherings and cancellation of almost all sporting events, performances, and public and private meetings that cannot be convened by phone. Consider school closures. Issue widespread ‘stay at home’ directives for public and private organizations, with nearly 100% telework for some, although critical public services and infrastructure may need to retain skeleton crews. Law enforcement could shift to focus more on crime prevention, as routine monitoring of storefronts could be important.

In this vision of turnkey totalitarian control of society, the vaccine was pre-approved: “Partner with pharmaceutical industry to produce anti-virals and vaccine.”

The National Security Council was put in charge of policy making. The CDC was just the marketing operation. That’s why it felt like martial law. Without using those words, that’s what was being declared. It even urged information management, with censorship strongly implied.

The timing here is fascinating. This document came out on a Friday. But according to every autobiographical account – from Mike Pence and Scott Gottlieb to Deborah Birx and Jared Kushner – the gathered team did not meet with Trump himself until the weekend of the 14th and 15th, Saturday and Sunday. 

According to their account, this was his first real encounter with the urge that he lock down the whole country. He reluctantly agreed to 15 days to flatten the curve. He announced this on Monday the 16th with the famous line: “All public and private venues where people gather should be closed.”

This makes no sense. The decision had already been made and all enabling documents were already in circulation. 

There are only two possibilities. 

One: the Department of Homeland Security issued this March 13 HHS document without Trump’s knowledge or authority. That seems unlikely. 

Two: Kushner, Birx, Pence, and Gottlieb are lying. They decided on a story and they are sticking to it. 

Trump himself has never explained the timeline or precisely when he decided to greenlight the lockdowns. To this day, he avoids the issue beyond his constant claim that he doesn’t get enough credit for his handling of the pandemic.

With Nixon, the famous question was always what did he know and when did he know it? When it comes to Trump and insofar as concerns Covid lockdowns – unlike the fake allegations of collusion with Russia – we have no investigations. To this day, no one in the corporate media seems even slightly interested in why, how, or when human rights got abolished by bureaucratic edict. 

As part of the lockdowns, the Cybersecurity and Infrastructure Security Agency, which was and is part of the Department of Homeland Security, as set up in 2018, broke the entire American labor force into essential and nonessential.

They also set up and enforced censorship protocols, which is why it seemed like so few objected. In addition, CISA was tasked with overseeing mail-in ballots. 

Only 8 days into the 15, Trump announced that he wanted to open the country by Easter, which was on April 12. His announcement on March 24 was treated as outrageous and irresponsible by the national press but keep in mind: Easter would already take us beyond the initial two-week lockdown. What seemed to be an opening was an extension of closing. 

This announcement by Trump encouraged Birx and Fauci to ask for an additional 30 days of lockdown, which Trump granted. Even on April 23, Trump told Georgia and Florida, which had made noises about reopening, that “It’s too soon.” He publicly fought with the governor of Georgia, who was first to open his state. 

Before the 15 days was over, Congress passed and the president signed the 880-page CARES Act, which authorized the distribution of $2 trillion to states, businesses, and individuals, thus guaranteeing that lockdowns would continue for the duration. 

There was never a stated exit plan beyond Birx’s public statements that she wanted zero cases of Covid in the country. That was never going to happen. It is very likely that the virus had already been circulating in the US and Canada from October 2019. A famous seroprevalence study by Jay Bhattacharya came out in May 2020 discerning that infections and immunity were already widespread in the California county they examined. 

What that implied was two crucial points: there was zero hope for the Zero Covid mission and this pandemic would end as they all did, through endemicity via exposure, not from a vaccine as such. That was certainly not the message that was being broadcast from Washington. The growing sense at the time was that we all had to sit tight and just wait for the inoculation on which pharmaceutical companies were working. 

By summer 2020, you recall what happened. A restless generation of kids fed up with this stay-at-home nonsense seized on the opportunity to protest racial injustice in the killing of George Floyd. Public health officials approved of these gatherings – unlike protests against lockdowns – on grounds that racism was a virus even more serious than Covid. Some of these protests got out of hand and became violent and destructive. 

Meanwhile, substance abuse rage – the liquor and weed stores never closed – and immune systems were being degraded by lack of normal exposure, exactly as the Bakersfield doctors had predicted. Millions of small businesses had closed. The learning losses from school closures were mounting, as it turned out that Zoom school was near worthless. 

It was about this time that Trump seemed to figure out – thanks to the wise council of Dr. Scott Atlas – that he had been played and started urging states to reopen. But it was strange: he seemed to be less in the position of being a president in charge and more of a public pundit, Tweeting out his wishes until his account was banned. He was unable to put the worms back in the can that he had approved opening. 

By that time, and by all accounts, Trump was convinced that the whole effort was a mistake, that he had been trolled into wrecking the country he promised to make great. It was too late. Mail-in ballots had been widely approved, the country was in shambles, the media and public health bureaucrats were ruling the airwaves, and his final months of the campaign failed even to come to grips with the reality on the ground. 

At the time, many people had predicted that once Biden took office and the vaccine was released, Covid would be declared to have been beaten. But that didn’t happen and mainly for one reason: resistance to the vaccine was more intense than anyone had predicted. The Biden administration attempted to impose mandates on the entire US workforce. Thanks to a Supreme Court ruling, that effort was thwarted but not before HR departments around the country had already implemented them. 

As the months rolled on – and four major cities closed all public accommodations to the unvaccinated, who were being demonized for prolonging the pandemic – it became clear that the vaccine could not and would not stop infection or transmission, which means that this shot could not be classified as a public health benefit. Even as a private benefit, the evidence was mixed. Any protection it provided was short-lived and reports of vaccine injury began to mount. Even now, we cannot gain full clarity on the scale of the problem because essential data and documentation remains classified. 

After four years, we find ourselves in a strange position. We still do not know precisely what unfolded in mid-March 2020: who made what decisions, when, and why. There has been no serious attempt at any high level to provide a clear accounting much less assign blame. 

Not even Tucker Carlson, who reportedly played a crucial role in getting Trump to panic over the virus, will tell us the source of his own information or what his source told him. There have been a series of valuable hearings in the House and Senate but they have received little to no press attention, and none have focus on the lockdown orders themselves. 

The prevailing attitude in public life is just to forget the whole thing. And yet we live now in a country very different from the one we inhabited five years ago. Our media is captured. Social media is widely censored in violation of the First Amendment, a problem being taken up by the Supreme Court this month with no certainty of the outcome. The administrative state that seized control has not given up power. Crime has been normalized. Art and music institutions are on the rocks. Public trust in all official institutions is at rock bottom. We don’t even know if we can trust the elections anymore. 

In the early days of lockdown, Henry Kissinger warned that if the mitigation plan does not go well, the world will find itself set “on fire.” He died in 2023. Meanwhile, the world is indeed on fire. The essential struggle in every country on earth today concerns the battle between the authority and power of permanent administration apparatus of the state – the very one that took total control in lockdowns – and the enlightenment ideal of a government that is responsible to the will of the people and the moral demand for freedom and rights. 

How this struggle turns out is the essential story of our times. 

CODA: I’m embedding a copy of PanCAP Adapted, as annotated by Debbie Lerman. You might need to download the whole thing to see the annotations. If you can help with research, please do.

*  *  *

Jeffrey Tucker is the author of the excellent new book 'Life After Lock-Down'

Tyler Durden Mon, 03/11/2024 - 23:40

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Government

Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says

Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President…

Published

on

Trump "Clearly Hasn't Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.

Robert F. Kennedy Jr. holds a voter rally in Grand Rapids, Mich., on Feb. 10, 2024. (Mitch Ranger for The Epoch Times)

During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”

President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”

An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”

“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.

“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.

“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”

Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”

Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.

Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.

President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.

Vice President Mike Pence (L) and President Donald Trump deliver an update on Operation Warp Speed in the Rose Garden of the White House in Washington on Nov. 13, 2020. (Mandel Ngan/AFP via Getty Images)

Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.

President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”

President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.

“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”

On many occasions, President Trump has said that he is not in favor of vaccine mandates.

An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.

Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.

He has criticized Big Pharma, vaccine safety, and government mandates for years.

Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.

“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.

“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”

Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.

President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.

COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.

Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.

Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.

John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.

Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.

Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.

“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.

During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.

President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.

He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.

President Donald Trump greets the crowd before he leaves at the Operation Warp Speed Vaccine Summit in Washington on Dec. 8, 2020. (Tasos Katopodis/Getty Images)

MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.

Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.

She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.

“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.

“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”

President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.

President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.

“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.

“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.

“America needs President Trump.”

Multiple national polls back Mr. Farno’s view.

As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).

A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.

The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.

The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.

It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.

The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.

Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.

Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.

A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.

The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.

President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.

Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.

I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.

“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.

“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”

Tyler Durden Mon, 03/11/2024 - 17:00

Read More

Continue Reading

Trending